ReviewMolecular cancer2026
The pre-metastatic niche: mechanisms, heterogeneity, and therapeutic opportunities.
Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Reprogramming pulmonary B cells by ANXA1 silencing halts lung metastatic niche formation in breast cancer.Journal of nanobiotechnology · 2026Article
- Review
- Article
- Glioma-derived extracellular vesicles as drivers of immunotherapeutic resistance: mechanisms of immune reprogramming and metabolic intervention.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Metastasis remains the leading cause of cancer-related mortality. The concept of the pre-metastatic niche (PMN) has provided a new framework for understanding how tumors establish favorable conditions in distant organs before metastatic colonization. This review delineates the cellular and molecular hallmarks of PMN, including immune suppression, vascular/lymphatic remodeling, metabolic reprogramming, and stromal reorganization, and traces their spatiotemporal evolution from initiation to colonization. It further examines the origins of metastatic lesions, with a focus on circulating tumor cells (CTCs) and stromal stem-like cells, highlights the pivotal role of extracellular vesicles (EVs) in mediating intercellular communication, metabolic reprogramming, and therapeutic applications. Deciphering the immune and stromal determinants of PMN formation offers key mechanistic insight into organ-specific metastasis. Consequently, this review explores translational strategies targeting the PMN, such as biomarker development, spatiotemporal profiling aided by artificial intelligence (AI), and immune, metabolic, or EV-based interventions. Deciphering PMN biology is therefore poised to open new avenues for the early interception and treatment of metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.